US WorldMeds® Receives Full U.S. FDA Approval of TECELRA® (afamitresgene autoleucel) with an Expanded Indication, Extending the First Approved Engineered T-Cell Therapy for a Solid Tumor to Children as Young as 12
Eligibility extends to patients with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and meet HLA and MAGE-A4 eligibility criteria LOUISVILLE, Ky., June 22, 2026 /PRNewswire/ -- USWM CT, LLC (US WorldMeds) announced that the U.S. Food and Drug...
Eligibility extends to patients with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and meet HLA and MAGE-A4 eligibility criteria LOUISVILLE, Ky., June 22, 2026 /PRNewswire/ -- USWM CT, LLC (US WorldMeds) announced that the U.S. Food and Drug...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.